Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6).
- Citation:
- J Clin Oncol vol 40 (16_suppl) TPS607
- Meeting Instance:
- ASCO 2022
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Funding:
- AFT
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- Sanofi
- Grants:
- Corr. Author:
- Authors:
- Thomas Meyskens Otto Metzger Coralie Poncet Theodora Goulioti Eleni Xenophontos Lei Wang Giovanna Rossi Heidi De Swert Jose Casas Sandrine Anneheim Amal Arahmani Laura Demeulemeester Christina Herold Gautier Paux Amylou Dueck Etienne Brain David Cameron
- Networks:
- LAPS-MA036, LAPS-MN026
- Study
- AFT-55
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: